Apply here
Instituto De Oncología Intervencionista  en

Instituto De Oncología Intervencionista’s poster “Superselective intraarterial and intrathecal combination chemotherapy in the compassionate management of diffuse intrinsic pontine glioma”

The Instituto de Oncología Intervencionista (IDOI México) is a multidisciplinary oncology team willing to try and change for the improvement of the oncological patient.

Last week, officially supported by our local oncology scene, IDOI México presents for the first time our findings in SMeO's 6th International & 37th National Oncology Congress, here in México.

Our program prolongs life, improves quality of life, and most importantly, we know we can still improve on these results.

-Dr. Alberto Siller Aguirre, Pediatric Oncologist.


“Superselective intraarterial and intrathecal combination chemotherapy in the compassionate management of diffuse intrinsic pontine glioma” by Alberto Siller Aguirre & Alberto Garcia de la Fuente from Instituto de Oncología Intervencionista (IDOI Mexico)

Our treatment, Superselective intraarterial and intrathecal combination chemotherapy (SSIAITCC) which we call "IDOI-1" represents a therapeutic benefit increasing overall survival and quality of life in pediatric patients diagnosed with DIPG.

Let's talk about these two characteristics: survival and quality of life.


The Kaplan-Meier curve is a statistical tool used to estimate the survival in medical research. 

Fig1. Kaplan-Meier curves representing global survival of DIPG IDOI vs SIOPE DIPGR

This graph shows in a dotted line the Kaplan-Meier curve from the data collected by the DIPGR in the biggest study on DIPG in children to date, with patients of many countries of origin, different ages of diagnosis, various stages of progression, and treatments. Their data shows that half of the pediatric DIPG patients would die by 11 months after diagnosis, then 90,4% by two years and 97,8% by five years and this has been the reality for the families in the last 60 years.

The continuous line in the graph represents our results from data collected from 69 cases of pediatric DIPG patients from february 2016 to july 2019 that share the same characteristics from the DIPGR population (countries of origin, etc) but were treated with SSIAITCC, IDOI-1, improving their overall survival to 19,4 months, with a 89,1% survival at one year post diagnosis and 33,4% at two years.

This demonstrates that IDOI-1 allows for a longer survival.


When discussing DIPG, a lot has been said about survival rates, but one thing that is not usually taken into account is the child’s general well-being and capability to carry everyday tasks, quality of life. Which has always been the centerpiece of our discussion when developing our treatment as well as when considering improvements.

We strongly believe that there is no use in prolonging the suffering, the hospitalization time, increasing the costs, but there is much value in regaining and preserving quality of life.

Why? Because disease may take your body or your life, but it can also affect your joy, and in children, it can take their childhood. None of this is what we would want for our own families.

In our poster, our measurements on quality of life were done using the Karnofsy / Lansky performance scale (KPS), which represents the patients activity status at the time of evaluation.

In the initial clinical evaluation of our patients, results varied from 30% up to a 100% (mostly from recently diagnosed or recently radiated patients) upon arrival. The median patient started our treatment with a 60% KPS, meaning: ambulatory up to 50% of the time, limited active play with assistance/supervision. Many of them not being able to walk, talk or eat and drink.

All of the patients treated with IDOI-1 presented improvement, some of them recovering all of their functions and being able to go back to their normal lives, school, do sports, be a kid. This is represented with a peak median KPS of 90% measured during follow up, a minor restriction in physical strenuous play.

Of course, our treatment still not being a cure means that these improvements were sustained for a time. However, with our most recent improvements, this time could be far longer.

And hopefully, a solid step towards a final cure.

You can find the complete transcription of the poster in english and make your own opinion in: